


Product Name : NMS-P937
Cat. No. : PC-22312
CAS No. : 1034616-18-6
Molecular Formula : C₂₄H₂₇F₃N₈O₃
Molecular Weight : 532.53
Target : Polo-like Kinase (PLK)
Solubility : 10 mM in DMSO



Biological Activity

NMS-P937 (Onvansertib, NMS-1286937) is a potent, selective and orally available PLK1 inhibitor with IC₅₀ of 2 nM, >300-fold selective over PLK2/3.

NMS-P937 exhibits antiproliferative effect on A2780 cells with IC₅₀ of 42 nM.

NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration.

NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine.

References

Beria I, et al. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74.

Valsasina B, et al. Mol Cancer Ther. 2012 Apr;11(4):1006-16.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com